Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

AIMS: We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. MATERIALS AND METHODS: We recr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Akinori, Shimizu, Miho, Hamaguchi, Erika, Kakuda, Hirokazu, Ikeda, Kenzo, Okumura, Toshiya, Kitagawa, Kiyoki, Koshino, Yoshitaka, Kobayashi, Motoo, Takasawa, Kazuya, Hisada, Yukimasa, Toyama, Tadashi, Iwata, Yasunori, Sakai, Norihiko, Wada, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375122/
https://www.ncbi.nlm.nih.gov/pubmed/32704573
http://dx.doi.org/10.1002/edm2.159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375122/
https://www.ncbi.nlm.nih.gov/pubmed/32704573
http://dx.doi.org/10.1002/edm2.159

Ejemplares similares